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Alzheimer’s disease (AD) is a neurodegenerative disease which is the 6
th
 leading cause of 
death in the US. AD pathology is thought to be linked to the accumulation and aggregation of 
toxic proteins, amyloid-beta and tau. AD development and neurodegeneration is proposed to be 
caused by the toxic effects of these protein accumulations, specifically amyloid-beta, as 
postulated by the amyloid-cascade hypothesis. To study the relationship between amyloid-beta 
and overall neuronal health, a study was carried out using an amyloid-expressing fruit fly 
photoreceptor model. Using this model, toxicity of amyloid in a stressed lysosomal system 
induced by light, an established lysosomal stressor to the fly eye, was assessed. Exposure to light 
increases neurodegeneration in amyloid-expressing photoreceptors. Furthermore, light exposure 
normally induces endocytosis and lysosomal degradation of rhodopsin, but rhodopsin 
accumulates in intracellular puncta in amyloid-expressing photoreceptors exposed to light. 
Subsequently, it was postulated that the endolysosomal defects of these photoreceptors are 
exacerbated when exposed to light, due to bulk endocytosis of rhodopsin.  To test this theory, the 
formation of rhodopsin was blocked by raising flies without vitamin A. Inhibiting rhodopsin 
formation dramatically rescued light-dependent photoreceptor degeneration. Experiments are 
underway to block the firing of action potentials in amyloid-expressing photoreceptors by co-
expressing an inward-rectifying potassium channel. This will differentiate between degeneration 
caused by rhodopsin endocytosis and that caused by neuronal activity. Additionally, the 
endolysosomal defect observed in amyloid-expressing photoreceptors is being characterized by 
means of colocalization studies. To identify the organelles containing rhodopsin accumulations, 
immunofluorescent staining for endosomes, lysosomes, and autophagosomes will be carried out. 
Findings thus far indicate that the presence of amyloid-beta does exacerbate endolysosomal 
dysfunction and neurodegeneration. By characterizing the exact defect in this pathway involved 
   
4 
 
in rhodopsin accumulation, information gleaned will shed light on the underlying flawed 
mechanisms in AD pathology. Such insights will inform a more detailed understand of AD 
development and progression. This will in turn allow medical researchers to identify and or 
advance novel therapeutics targeting these defects, providing a much needed solution to a tragic 
disease with few effective therapies available to treat victims.  
Introduction  
Alzheimer’s Disease: 
 Alzheimer’s disease (AD) is a neurodegenerative disease in which structural changes 
occur in the brain in conjunction with neuronal death. This neurodegeneration typically occurs 
over the course of an individual’s lifetime, the average age of onset of AD symptoms is 65 years 
of age. Subsequently, AD is known as an aging disease as incidence of diagnosis soars in direct 
relation to age. For example, approximately 50% of individuals aged 85 and older in the US are 
diagnosed with AD (Casey et al. 2010).  Neurodegeneration associated with AD causes dementia 
which is the loss of basic social and thinking skills. Other symptoms of AD are memory loss, 
disorientation, non-memory cognitive deficits, and visuospatial issues. These symptoms typically 
begin mildly and progress from moderate to severe over the course of several years (National 
Institute on Aging, 2016).  
In 2017, 5.3 million Americans were diagnosed with AD. 200,000 of those individuals 
were under 65 and had been diagnosed with familial early onset AD in the United States. 
Familial early onset AD is a subset of this disease caused by genetic mutations. However, the 
majority of AD cases are late onset type and are not thought to be solely the result of genetic 
mutation. Worldwide, AD afflicts 44 million people, and its incidence is projected to rise 
markedly in the future given the increase in the rate of diagnosis in the past twenty years. As AD 
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progresses, victims require assistance carrying out basic activities, such as dressing oneself. This 
creates an exorbitant demand for care of AD victims. It is estimated that 15 million Americans 
provide unpaid care for victims of AD. This brings the medical cost of AD in the US to $230 
billion in 2017 alone due to lost wages associated with providing unpaid care to loved ones, as 
well as the cost of professional and medical assistance (Alzheimer’s Association, 2017). The 
rising prevalence of AD places a severe financial and medical burden across our nation and the 
world. Such need demands medical treatments that are effective in prolonging and improving 
victims’ quality of life, cognition, and overall mental well-being.  
Current Treatments: 
The damage incurred to the brains of AD victims is irreversible and progressive. 
Neurodegeneration cannot be reversed because currently there is a paucity of knowledge 
regarding how to regenerate neurons in the human brain. At this time, there are only drugs 
approved in the United States which act as disease-modifying therapies for treatment of AD. 
Specifically, these drugs target molecules to increase or decrease the activities of certain 
neurotransmitters in the brain thought to maintain mental function and temper behavioral issues 
associated with AD. To date, there are five drugs approved by the Food and Drug Administration 
(FDA) to be used in the treatment of AD in the US. Four of these drugs are Cholinesterase 
Inhibitors (CI) which increase the amount of available acetylcholine, a neurotransmitter 
associated with learning and memory used to transduce signals between the synapses of neurons. 
CIs are typically used in the mild to moderate stage of AD. Donepezil, brand name Aricept, is 
the only CI that has been approved by the FDA to be used in the severe stages of AD. The fifth 
drug available is a NMDA receptor antagonist which acts to reduce the amount of glutamate 
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signaling in synapses, thought to help slow the progression of neuronal death in moderate to 
severe stages of AD (Casey et al. 2010).  
Although there are drugs which have shown to have some efficacy in the treatment of 
symptoms associated with AD, effectiveness of these drugs has not proven to be very strong. 
Patients with mild AD symptoms prescribed CIs show a 1.5 point increase in the Mini Mental 
State Examination (MMSE) test, an exam used to assess overall cognitive function. However 
scores on the MMSE drop below baseline six to nine months after starting treatment. 
Additionally, CIs are reported to have gradual dose escalation, in which a greater dose of drug is 
required to yield a therapeutic effect, but simultaneously induces a greater magnitude of 
undesirable side effects such as nausea and diarrhea (National Institute on Aging, 2016). It is 
estimated that only 50% of subjects show any benefit to treatment with CIs. Furthermore, 
Donepezil shows no benefit in comparison to placebo in clinical trials attempting to modulate 
agitation, a symptom common in AD. In sum, drugs available for the treatment of AD are merely 
palliative in their benefits, which are limited for many patients. This lack of effectiveness, in 
combination with the cost of these drugs, which is estimated on average to be $1800 per year, 
leaves much to be wanted in terms of treatment of AD (Casey et al. 2010). These issues 
underscore the significance of biomedical research being carried out today aimed at elucidating 
the causes of AD. Information derived from these studies can identify novel targets for 
therapeutics as well as potential mechanisms to stop neurodegeneration all together.  
Pathology of Alzheimer’s Disease 
Neuronal dystrophy and death, vascular alterations, and abnormal deposition of 
neurotoxic proteins are observed in the brains of AD victims (De Strooper and Karren, 2016). 
These protein aggregates form two different structures, plaques and tangles (Figure 1). Plaques 
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are composed predominantly of Aβ42 protein, a derivative of a generally nontoxic 
transmembrane protein Amyloid Precursor Protein (APP). Aβ42, or amyloid-beta, is an insoluble 
oligomer that accumulates extracellularly in the central nervous system (CNS) and the cerebral 
cortex. Neurofibrillary tangles are intracellular structures composed of hyperphosphorylated tau, 
a protein involved in the stabilization of microtubules (Casey et al. 2010). It is thought that 
aggregation of these proteins and neuronal death precedes onset of symptoms by several decades 
(De Strooper and Karren, 2016).  
 
Figure 1. Visualization of plaque and neurofibrillary tangle accumulations in the brain of an AD 
victim adapted from LaFerla and Dick-Muehlke, UC Irvine Institute for Neurological Impairments 
and Neurological Disorders. 
The relationship between aggregation of Aβ42 and tau and neurodegeneration is ill-
defined. The predominate theory in this field, the amyloid cascade hypothesis emphasizes 
amyloid-beta accumulation as the causative force responsible for neurodegeneration. More 
specifically, this hypothesis postulates that the increased formation of insoluble Aβ42 oligomers 
leads to its extracellular aggregation in the CNS. Such aggregation leads to neuronal dysfunction 
and death and subsequent formation of neurofibrillary tangles. A strength of this hypothesis is 
that is brings together the pathology and symptoms of AD, as well as genetic mutations 
associated with familial AD. However, this theory hypothesizes a linear set of events which have 
   
8 
 
been found to not necessarily true in human and mouse model studies. Additionally, any 
potential interaction between amyloid-beta and tau accumulations has been ignored (Karren et al. 
2011). Therefore, there is incomplete evidence and information as to the exact relationship 
between amyloid and tau accumulations and neuronal death in AD. Further work must be carried 
out to define these relationships to further provide insight on the etiology of this disease.  
How toxic proteins are degraded 
 An important factor to consider when investigating amyloid-beta and tau protein 
accumulations is the mechanisms cells use to degrade toxic proteins. Cells degrade material by 
the autophagy-lysosomal system (ALS) or the ubiquitin-proteasome system (UPS) (Ghavami et 
al. 2014). In the UPS, proteins are targeted for degradation by means of an ubiquitin tag which 
targets them to the proteasome. These proteins are then cleaved into their amino acid monomers 
by the proteasome (Figure 2). Autophagy is carried out when a cell engulfs and digests part of its 
intracellular material. This process is thought to be induced by starvation or stress signals 
propagating throughout the cell. Upon engulfment of material an autophagosome is formed 
which fuses with the lysosome to be digested by low pH and hydrolytic enzymes (Nixon et al. 
2005). Additionally, in the endocytic pathway extracellular organic material is engulfed in to a 
vesicle called an endosome. The endosome undergoes varies internal changes through the actions 
of trafficking proteins to form an intermediate and then late endosome. The late endosome fuses 
with the lysosome which degrades its contents (Figure 3). Both the UPS and ALS degrade 
intracellular organic material while the endocytic pathway intakes and eliminates extracellular 
substrates. The UPS is more limited in the substrates, primarily proteins, it can degrade in 
comparison to the ALS. Furthermore, the ALS sequesters its substrates in membrane-bound 
vesicles which undergo a maturation process to eventually fuse with the lysosome, a process not 
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entirely understood. Meanwhile, the UPS covalently modifies proteins thereby targeting them for 
degradation.  
 
Figure 2. Schematic of series of events carried out in ubiquitin-proteasome system (UPS) adapted 
from Rubinsztein (2006). Prior to trafficking to the proteasome proteins are covalently modified with 
ubiquitin. This modification is carried out by ubiquitin-activating, ubiquitin conjugating, and ubiquitin 
ligase enzymes, termed E1, E2, and E3 respectively in this diagram. Proteins tagged with ubiquitin are 
trafficked to the proteasome by chaperone proteins CDC48/p97. Upon arriving at the proteasome, 
proteins are broken into their peptide sequences and then degraded to their amino acid monomers by 
cytosolic peptidases (Rubinsztein, 2006).  
 
   
10 
 
Figure 3. Schematic of the processes carried out in the autophagy-lysosome system (ALS) adapted 
from Castro-Obregón (2010). Autophagy is carried out initially by engulfment of cellular material to 
form a phagophore. Intracellular changes occur in the phagophore through a process of maturation, 
forming an autophagosome. The autophagosome can then fuse with the lysosome to form an 
autolysosome or with late endosomes to form an amphisome. The endocytic pathway converges into this 
the autophageal pathway. Early endosomes sequestering extracellular material and undergo a process of 
maturation. Late endosomes fuse with the lysosome and their contents digested (Castro-Obregón, 2010).  
Given that amyloid-beta and tau are accumulating in the brain in AD, either the UPS or 
ALS, or both of these protein degradative systems are defective. Amyloid-beta protein cannot be 
degraded by the UPS because it is such an organically stable oligomer. This leaves amyloid-beta 
to be degraded by the ALS (Ihara et al. 2012). Interestingly, studies have found autophagosomes 
in brain sections of AD victims, which are not normally found in the CNS of healthy individuals. 
These studies have also found autophagosomes to be adjacent to amyloid-containing plaques 
(Figure 4). Furthermore, in Presenilin 1/Amyloid Precursor Protein (PS1/APP) mice, a model of 
familial AD, both presenilin and amyloid-beta peptides immunocolocalize with autophagosomes 
(Figure 5). This is thought to be the result of amyloid-beta peptides being generated from the 
breakdown of APP-containing organelles by autophagy. Researchers have hypothesized that in 
AD autophagosome maturation is somehow inhibited, increasing the amount pre-lysosomal 
autophagosomal intermediates in the neurons leading to failure of the ALS and cell death 
(Nixon, 2007). This highlights the question of whether the autophagosomes are a response to 
amyloid accumulation, or are somehow impeded thereby resulting in the inhibition of plaque 
degradation. This evidence supports the theory that autophagy is involved in AD pathogenesis, 
but to what capacity it remains unknown.  




Figure 4. Autophagosomes are visualized to be in close vicinity to amyloid plaques and sites of 
neuronal dystrophy in AD victims’ brains adapted from Nixon et al. (2005). Autophagosomes were 
visualized via electron microscopy using Ig-gold in the cross section of the brain. The accumulation of 
these vesicular bodies near plaque formations and neuronal loss are marked with arrowheads (Nixon et al. 
2005).  
 
Figure 5. In PS1/APP mouse brains amyloid-beta peptide and presenilin 1 have been found to 
colocalize with autophagosomes adapted from Nixon (2007). A. Antibodies conjugated to gold 
particles localize to PS1 within amyloid-containing neuritic plaques. B. Immuno-gold staining of PS1 
demonstrates that this protein is present on the membrane of autophagosomes. C. Silver-enhanced Ig-gold 
staining of Aβ42 (shown in dark black) localizes within autophagosomes, the distinctive vesicles outlined, 
in dystrophic neurons (Nixon, 2007). 
Experimental Questions 
   
12 
 
This study focused on the following questions probing the role of amyloid-plaque 
formation in AD: Given the protein degradative machinery in our cells, how is Aβ42 
aggregating? Furthermore, how does the accumulation of Aβ42 lead to neurodegeneration? 
Specifically, this experimentation explored whether the ALS is defective in the presence of Aβ42 
given recent evidence of the role of autophagy in this disease. Additionally, an aim of this study 
was to identify the exact defect in this system that leads to plaque formation. In aiming to 
understand these questions the link between neurotoxic amyloid protein aggregation and 
neuronal death can be further defined. Information generated from these studies can be used to 
determine novel targets or strategies to treat AD.  
Experimental Design 
 To carry out experimentation, a Drosophila melanogaster (fruit fly) animal model was 
used to model Aβ42 accumulation in neurons. This model was used given that Drosophila is an 
established model system and its well-defined genetics. Additionally, gene manipulation can be 
carried out simply and effectively using transgenes. Moreover, fruit flies are easy to care for and 
have a fast generation time of approximately nine days. The neuron of the fruit fly also possesses 
similarity to that of the human neuron (Bellen et al. 2010). Consequently, the neurons of the fly 
eye, or photoreceptors, expressing Aβ42 were used as a model of a human neuron to understand 
the how this protein affects the ALS and overall neuronal health. By studying this aspect of AD 
and defining the relationship between amyloid-beta protein and the ALS, insights can be gained 
regarding AD pathogenesis. A weakness of this model system is that it is an artificial model of 
AD as this disease is much more complex in terms of proteins and cell populations involved in 
neuronal dystrophy and death.  
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 Another reason the fly eye was chosen is due to the established lysosomal stress of light 
in Drosophila melanogaster. Light induces stress in the ALS because it is thought that this light 
exposure induces the increased endocytosis of rhodopsin, a G-Protein Coupled Receptor (GPCR) 
protein associated with the structure of the retina. It has been proven that Drosophila neurons 
with impaired lysosomal function degenerate when they are overwhelmed by rhodopsin 
(Chincore et al. 2009). In this study, it was hypothesized that the presence of amyloid-beta 
protein in Drosophila sensitizes photoreceptors to endolysosomal defects when exposed to light 
due to bulk endocytosis of rhodopsin. From this hypothesis it was predicted that exposing 
amyloid-expressing flies to light would exhibit more neuronal degeneration than those flies 
reared in the dark. Further studies focused on the role of rhodopsin in Aβ42-induced 
degeneration (A full description of methods can be found in Materials and Methods section).  
Results 
Light makes amyloid-beta more toxic to photoreceptors 
 To assess whether Aβ42 makes photoreceptors more sensitive to the toxic effects of light, 
GMR-Gal4Aβ42 expressing flies were raised for three weeks in either a light or dark 
condition. Microdissection, immunofluorescent staining and imaging were carried out. The 
remaining rhabdomeres per ommatidium, each discrete facet of the fly eye, were counted to 
score neurodegeneration. Rhabdomeres, which are seven light sensing rhodopsin-containing 
structures, were visualized using phalloidin, a fluorescent dye which binds to cortical actin. To 
determine whether the presence of Aβ42 in the flies manifested some toxicity and was not the 
result of just light exposure alone, both the light and dark conditions were compared to a 
negative control, a wildtype fly which did not express transgenes. Staining of the eye showed 
that the wildtype fly displayed no neurodegeneration after aged in the light for three weeks 
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(Figure 6, A). Comparing this control to the amyloid-expressing fly in the dark condition, some 
neurodegeneration is seen with an average of 6.22 ± 0.16 rhabdomeres remaining for (Figure 6, 
B). This difference demonstrates that Aβ42 induces some kind of toxic effect on the flies, 
indicating that amyloid-beta expression was successfully modeled in the fly. For amyloid-
expressing flies raised in the light condition, increased neurodegeneration was observed with 
only 5.36 ± 0.14 rhabdomeres remaining (Figure 6, C).  
 
Figure 6. Amyloid-expressing flies raised in the light show more degeneration than those raised in 
the dark.  A. Eye from a wild type fly which acted as a negative control. The ommatidia are organized 
and each facet contains seven discrete units, rhabdomeres, indicating little if any degeneration has taken 
place.  B. Eye from an amyloid-expressing fly raised in the dark. The structure of the eye is less organized 
and there are approximately six rhabdomeres per ommatidia.  C. Eye from an amyloid-expressing fly 
raised in the light. The structure of the eye is fairly disorganized and there are visually four to five 
rhabdomeres per ommatidia.  
 Analysis of the neurodegeneration observed in these light and dark conditions in the 
amyloid expressing flies found that the difference between these two groups to be statistically 
significant, p = 0.0009 (Figure 7). This finding indicates that the presence of amyloid in the light 
does induce a significant increase in photoreceptor degeneration.  




Figure 7. Scoring of neurodegeneration of amyloid-expressing flies between light and dark 
conditions and with and without amyloid-beta expression. Neurodegeneration was scored by number 
of rhabdomeres per ommatidia left. The box and whiskers represents the interquartile range of the data 
with lines representing the minimum, average, and maximum values of the data set. There is no 
neurodegeneration in the negative control. There are on average 6.22 ± 0.16 (n = 10 eyes) rhabdomeres 
per ommatidium remaining for the amyloid-expressing dark reared flies. There are 5.36 ± 0.14 (n = 8) 
rhabdomeres remaining in the amyloid-expressing flies reared in the light. A Two-Tailed Student T-test 
found the difference between the light and dark conditions was found to be p = 0.0009. 
Rhodopsin exacerbates amyloid-beta toxicity in photoreceptors 
 In an effort to understand the contributing sources to the light-dependent degeneration 
observed, the question was asked whether rhodopsin endocytosis was solely responsible for this 
cell death. To test this question, rhodopsin formation in the flies was inhibited by raising them on 
a vitamin A deficient diet. Vitamin A is a required compound needed to form retinol, an opsin 
protein that is a part of the rhodopsin complex. Therefore, without vitamin A rhodopsin would 
not form in the flies. Amyloid-expressing flies were raised on a vitamin A deficient diet and the 
photoreceptor degeneration compared to amyloid-expressing flies raised on normal food for the 
light condition (Figure 8, B, C). Qualitatively speaking, the structure of the eye is more 
organized and more rhabdomeres were observed in those flies raised on this medium. 
Additionally, to confirm that rhodopsin was not formed in these flies, eyes were stained 
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immunofluorescently for this protein. Little if any rhodopsin stain was observed, indicating that 
this protein was in fact not formed using this method (data not shown). 
 
Figure 8. Amyloid-expressing flies raised in the light in the absence of vitamin A exhibit rescue of 
light-dependent degeneration. A. Eye from a wild type fly reared in the light which served as a negative 
control. The structure of the ommatidia is organized and each facet contains seven discrete units 
indicating no degeneration has occurred. B. Eye from an amyloid-expressing fly in the light raised on 
normal food exhibiting significant degeneration and disorganization of the eye overall. C. Eye from an 
amyloid-expressing fly raised in the light on a vitamin A deficient diet. Although small, there are six to 
seven rhabdomeres present showing little degeneration has taken place. 
 
Statistical analysis indicates that inhibition of rhodopsin formation in photoreceptors 
significantly rescues the light-dependent degeneration found in the amyloid-toxicity experiment 
(p < 0.0001). On average, amyloid-expressing flies raised on vitamin A deficient media in the 
light had 6.779 ± 0.058 rhabdomeres remaining (Figure 9). Such a drastic rescue of this light-
dependent degenerative phenotype demonstrates the significance of rhodopsin as a mediator in 
neuronal loss in this model.   
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 ‘  
Figure 9. Comparison of neurodegeneration between amyloid-toxicity experiment and amyloid-
expressing flies reared without rhodopsin. Neurodegeneration was scored by counting the rhabdomeres 
left per ommatidium. The box and whisker plots for each condition show the interquartile range for each 
condition containing the minimum, average, and maximum values. There is no neurodegeneration in the 
negative control, wild type flies raised in the light. There is significant degeneration in the amyloid-
expressing flies reared in the light with an average of 5.36 ± 0.14 (n = 8 eyes) rhabdomeres remaining. 
The amyloid-expressing flies raising in the light on vitamin A deficient food showed significant rescue in 
neurodegeneration with an average of 6.779 ± 0.058 (n = 6) rhabdomeres remaining. The difference 
between the normal food light-reared flies and the vitamin A deficient flies was found to be statistically 
significant, p < 0.0001, using a Two-Tailed Student’s T test.  
Rhodopsin accumulation in the endolysosomal pathway in light-reared flies 
 In the amyloid-toxicity experiment, eyes from both light and dark conditions were 
immunoflourescently stained with for rhodopsin. In the light condition, amyloid-expressing flies 
exhibited rhodopsin puncta within and around ommatidia. This intensity of staining was not 
observed in the dark condition, demonstrating that in the light rhodopsin is accumulating 
somewhere in the endolysosomal system. This reveals a defect which is impairing degradation of 
this protein. This observation further supports the hypothesis that the ALS and endolysosomal 
system in amyloid-expressing flies are defective (Figure 10).  




Figure 10. Rhodopsin puncta are observed in light-reared amyloid-expressing flies. Amyloid-
expressing eyes were stained for actin and rhodopsin. Actin was stained for using phalloidin and is shown 
in magenta. Rhodopsin is shown in green. Actin staining is shown in the far left panel for each of the 
conditions, the middle rhodopsin. An overlay of these stains is shown on the far right. Comparing the 
light and dark conditions, there are accumulations of rhodopsin in the light, and little if any in the dark 
condition.  
Future Directions 
Two hypotheses of light-dependent neurodegeneration 
 The findings of this study point to the significant involvement of rhodopsin in the 
formation of a light-dependent neurodegenerative phenotype in this model. At this time, the 
exact mechanism by which rhodopsin mediates neurodegeneration is unknown. Two alternate 
hypotheses have been postulated to describe the events leading to this neurodegeneration (Figure 
11). The first is the Rhodopsin endocytosis hypothesis in which light induces rhodopsin to be 
endocytosed and targeted for degradation by the endolysosomal system. However, over time 
rhodopsin overwhelms this system with the added stress of Aβ42 expression impairing this 
pathway, leading to lysosomal dysfunction, failure, and neuronal death. Alternatively, the 
potential role of neuronal firing must be considered in mediating cell death in this model. 
Consequently, the second hypothesis is a Neuronal firing hypothesis in which light induces 
rhodopsin to undergo a conformational change and be “excited,” which in turn causes an action 
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potential to fire by the neuron to transmit a chemical message. Continual firing over time causes 
the neuron to age, and it eventually burns out and dies. 
 
Figure 11. Two alternate hypotheses proposed for the mechanism of light-dependent 
neurodegeneration. The Rhodopsin endocytosis hypothesis postulates that light induces rhodopsin to be 
endocytosed from the cellular membrane into the intracellular environment of the cell. The presence of 
Aβ42 impairs the ALS causing lysosomal dysfunction as it is overwhelmed by bulk rhodopsin 
endocytosis. Lysosomal failure leads to death of the neuron. In the Neuronal activity hypothesis light is 
proposed to cause rhodopsin to be excited and targeted for the endocytic pathway at the cellular 
membrane. The excitation of rhodopsin leads to the firing of an action potential by the neuron. Over time 
this firing of the neuron leads to neuronal dysfunction and death.  
 At this time, these two hypotheses cannot be differentiated. An experiment to 
characterize the potential involvement of neuronal firing has been planned. In this experiment 
Kir 2.1-expressing flies will be bred with GMR-Gal4Aβ42 expressing flies. Kir2.1 is an 
inward rectifying potassium channel in neurons. In Kir2.1-expressing flies normal polarization of 
the neuron is inhibited, thereby preventing neurons from firing (Hodge, 2009). Subsequently, 
breeding GMR-Gal4Kir2.1 to GMR-Gal4Aβ42 individuals, the progeny from this cross will 
express amyloid-beta in their eyes and their photoreceptors will not fire. These flies will be 
reared in the two light conditions and aged for three weeks. Eyes will be dissected, stained, and 
imaged as was done in the experiments carried out in this study. By inhibiting neuronal firing it 
can be determined to what capacity neuronal activity is contributing to the light-dependent 
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neurodegenerative phenotype. Some predictions for this experiment are that if similar light-
dependent degeneration is found for the light condition as found in the amyloid toxicity 
experiment, then neuronal firing is most likely not involved in this cell death. Such a finding 
would further support the Rhodopsin endocytosis hypothesis. Instead, if rescue of 
neurodegeneration is exhibited in the light condition, then this result would suggest that neuronal 
activity is involved, thereby supporting the  Neuronal firing hypothesis.  
Localization of rhodopsin accumulations in the endolysosomal system 
 As discussed in the results, rhodopsin was observed to be accumulating at increased 
levels in the light reared amyloid-expressing flies compared to the dark-reared individuals. Such 
a finding suggests a failure of the endolysosomal system. In order to identify the exact defect in 
this system studies have been proposed to replicate the amyloid-toxicity experiment and stain 
eyes with immunofluorescently for rhodopsin and markers of different compartments involved in 
the endolysosomal system. These compartments include fluorescent antibodies targeting the late 
endosome, autophagosome, and lysosome. The purpose of this staining will be to identify which 
compartment, or compartments, rhodopsin colocalizes with. Therefore, the location of rhodopsin 
accumulations can be elucidated and a detailed mechanism of defect can be proposed.  
Verification by electrophysiological methods 
 In order to verify the neurodegeneration quantified in these studies, verification by 
electrophysiological methods must be carried out. An electroretinogram (ERG) is a test in which 
electrodes monitor and record the electromagnetic field potential of the fly eye. Typically ERGs 
are measured in response to light and quantitation of visual transduction can be assessed by 
analyzing the differences in electromagnetic field potential through time (Vilinsky and Johnson, 
2012). Therefore, the amount of photoreceptor firing can be quantified in wildtype flies in 
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response to light and then be compared to amyloid-expressing flies both light and dark-reared.  
The recorded differences between the firing of these eyes will enable quantitation of cell death. 
This method of scoring of neurodegeneration will be performed for both the amyloid toxicity and 
the vitamin A deficient flies to verify conclusions drawn from the microscopy findings. 
Additionally, when carrying out the Neuronal firing hypothesis experiment, lack of neuronal 
firing in the Kir2.1-expressing can be verified.  
Conclusion  
Significance of findings for the fly eye model 
 In terms of analyzing the results in the context of the fly eye model used, rhodopsin-
mediated light-dependent degeneration appears to be specific to photoreceptors. There are 
approximately 100 peer reviewed articles published to date that use the fly eye model in studying 
neurodegenerative disease. Subsequently, the findings from this study highlights the conclusion 
that the scoring of neurodegeneration in these studies could be skewed by light as it could have 
had confounding effects on the results.   
 Reflecting more on the fly eye as model in relation to the study aims, the aspect of 
artificiality of this model must be accounted for. First, although a fly neuron is similar to that of a 
human neuron, the two are not equal in all aspects. Secondly, the amyloid-expressing fly does 
not account for the complexity of Alzheimer’s disease. Primarily, it must be emphasized that 
other proteins, such as hyper-phosphorylated tau, accumulate in AD. Additionally, there are 
many cell populations, such as glial cells, involved in the physiological changes occurring in the 
brain which are not addressed by this model. Rather, this model allows us to analyze the specific 
relationship between amyloid-beta and neuronal health. Additionally, a detail to note is that 
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rhodopsin acts as a stressor on the ALS in this model, rhodopsin is not relevant to AD 
pathogenesis in humans.   
Significance of findings to AD pathogensis 
 In the context of AD pathogenesis, the results of this study hold important implications 
for the treatment of AD patients and at-risk individuals. The findings do support the 
endolysosomal defect hypothesis initially postulated to the extent that amyloid-beta does appear 
to exacerbate endolysosomal defects present in the ALS when subject to stress. However, it is 
unclear at this time whether rhodopsin mediates neuronal death by ALS dysfunction or by mode 
of neuronal firing. The proposal of the Neuronal firing alternative hypothesis holds serious 
implications should neuronal activity is found to be involved neurodegeneration in this model. 
Specifically, the popular belief in the field of neuroscience is that a neuron does not die by means 
of use, but rather disuse. The Neuronal firing hypothesis is a contrary burn-out theory model. 
Typically individuals at risk for developing AD are told to “exercise” their brain such as doing 
puzzles, reading, and other activities that require cognitive exertion. If neuronal firing does prove 
to be involved in neurodegeneration, how the medical field treats at-risk individuals for AD will 
need to change.  
 The proposed experiments to localize where rhodopsin is accumulating in the 
endolysosomal system will shed light in the impairment in the ALS in the model. By identifying 
this defect, this information will allow us to better understand neurotoxic protein accumulation in 
AD. By defining this exact defect in the ALS, the findings from these experiments will enable 
superior therapeutics to be identified. For example, Rapamycin is a drug used to coat coronary 
stents, as well as has immunosuppressive effects in humans (American Chemical Society, 2016). 
Rapamycin has also been found to induce autophagy in cells (Cai, 2013). If conclusions from 
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this study reveal an inability for autophagosomes to mature and fuse with the lysosome, then 
treatment of AD with Rapamycin holds promise because this drug targets and enhances this 
pathway. This study and future experiments proposed have significant consequences for the 
identification of therapeutics which will aim to treat the underlying pathology of AD, rather than 
those that are merely symptom-modulating. This work will provide information to advance more 
meaningful options to the millions of victims of AD in the United States and around the world.  
Materials and Methods 
 A transgenic Aβ42 fruit fly was the experimental model used to carry out this study. This 
fly was made by breeding GMR-Gal4 expressing virgin female flies to UAS-Aβ42 expressing 
males. GMR-Gal4 drives expression of transgenes specifically in the fly eye. The UAS-Gal4 
driver system is widely used is in the scientific community to induce local expression of 
transgenes in Drosophila. The Gal4 gene encodes for a yeast transcriptional activator protein and 
directs transcription of genes downstream of the Upstream Activating Sequence (UAS), in this 
case the gene that codes for Aβ42 protein (Li et al. 2012). This cross produced a fly with 
expression of GMR-Gal4Aβ42 in its eye. Localized expression of Aβ42 was chosen for this 
study because global expression of amyloid-beta induces toxic effects that significantly shorten 
the lifespan of these flies (Prüßing, Voigt, & Schulz, 2013). GMR-Gal4 and UAS-Aβ42 stock 
flies were purchased from Bloomington Drosophila Stock Center at Indiana University.  
Initially, an experiment was carried out to assess amyloid toxicity in the fly eye. GMR-
Gal4Aβ42 progeny were collected at one day old and raised in two different conditions. One 
condition was the “light condition” in which the flies were exposed to 12 hours of light and 12 
hours of dark per day. The other condition was the “dark condition” in which the flies were aged 
in 24 hours of dark per day. The flies were aged for three weeks at 25º Celsius. The vials these 
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flies were aged in were changed once a week to resupply food (Bloomington Standard Medium) 
and prevent these flies from being mixed with their progeny, whose genotype was not known. In 
addition to assaying these flies, a negative control, a fly that expressed no transgenes was 
assessed as well. This control aimed to answer the question whether significant degeneration 
occurs in the light condition of healthy flies, and therefore if our method of scoring degeneration 
was confounded by light alone.     
 After three weeks flies from both the light and dark conditions expressing amyloid-beta 
and the wildtype controls were put under using carbon dioxide gas, their eyes were then 
microdissected in 3.7% paraformaldehyde fixative solution. After fixing eyes while shaking for 
30 minutes, eyes were washed with 1X PBS, further dissected to get rid of excess cuticle and 
stored in 1X PBS-Triton. The eyes were immunoflourescently stained with 1:500 dilution of 
TRIC-phalloidin, and 1:50 dilution of Rhodopsin 4C5 mouse antibody from the Developmental 
Studies Hybridoma Bank. Secondary goat anti-mouse 488 and goat anti-rabbit 647 antibodies 
from Abcam were used following primary staining in 1:500 dilutions. After completion of 
staining, eyes were mounted on slides using VectaShield. The eyes were imaged using an 
Olympus A-1 R confocal microscope in which 10µm Z-planes were take to obtain the most 
comprehensive view of the cells present.  
 After imaging, the number of rhabdomeres, seven visible light sensing structures, per 
ommatidium (facet of the eye) were counted using ImageJ software by three individuals to 
ensure consistency and accuracy of results. The average number of rhabdomeres per 
ommatidium left for each eye was calculated for both conditions (light and dark for both 
amyloid-expressing and wildtype flies). This data was used to perform a Two-Tailed Student T-
test to assess the differences between the conditions. 
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Following the amyloid toxicity experiment, a follow up experiment was carried out to 
assess whether rhodopsin was responsible for the light-dependent degeneration observed. 
Rhodopsin formation was prevented by raising GMR-Gal4Aβ42 expressing flies on vitamin A 
deficient food. Vitamin A deficient food was made according to Nichols and Pak, 1985 (Nichols 
and Pak, 1985). Then the UAS- Aβ42 x GMR-Gal4 cross was carried out in these food vials for 
both light and dark conditions. GMR-Gal4Aβ42 expressing progeny were isolated at one day 
old and then aged in their in light and dark conditions for three weeks at 25º Celsius. Following 
aging, microdissection of the eyes was carried out, followed by staining and imaging as 
previously described. This data was statistically analyzed using a Two-Tailed Student T-test to 
assess the differences between the conditions. The results of this experiment were compared to 
the amyloid toxicity experiment using a T-test. 
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